Products

Overall Expertise Manufacturing Facilities Research & Development

API

Our API – Other Pharmerging Markets Portfolio** consists of the following: Please Note - PhM DMF are shared on basis of customer request

Therapeutic Category	Name of API
Anti-cancer	Anastrozole
	Azacitidine
	Afatinib dimaleate
	Bicalutamide
	Belinostat
	Bortezomib
	Busulfan
	Cabazitaxel
	Carboplatin
	Carfilzomib
	Decitabine
	Docetaxel Trihydrate
	Docetaxel anhydrous
	Erlotinib
	Gefitinib
	Gemcitabine HCl
	Gemcitabine HCI (Alternate process)
	Irinotecan Hydrochloride Trihydrate
	Ibrutinib
	Letrozole
	Oxaliplatin
	Paclitaxel Semi-synthetic
	Pemetrexed Diacid
	Ribociclib Succinate
	Bendamustine Hydrochloride
	Alectinib HCl
	Plerixafor
	Imatinib Mesylate
Neuromuscular Reversal Drug	Sugammadex Sodium
Anesthetics	Bupivacaine Hydrochloride
	Levobupivacaine Hydrochloride
	Ropivacaine Hydrochloride Monohydrate
	Ropivacaine Hydrochloride Anhydrous
Antibiotic	Chloramphenicol hemisuccinate

**The buyer / customer should make their independent evaluation of the patent scenario for their respective markets, in respect of the API/formulations bought from Fresenius Kabi Oncology Limited, and they shall be solely and exclusively responsible for all patent related liabilities including any litigation by third party.

Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.

Top